AI marketing for IV and recovery therapy providers
The FTC's first action in this sector was against a marketer claiming IV cocktails treated serious disease. Everything you say about benefits has to survive that standard.
This is a wellness business on the outside and a sterile drug administration business on the inside, and the marketing has to respect the second one.
Written for claims that get checked.
Which IV therapy business are you?
A chain running lounges across markets, a single lounge with a treatment room, and a nurse driving to people's homes all administer the same infusions under very different operational constraints. Pick the one that matches what you run.
IV and recovery therapy use cases
Four jobs the platform runs on an IV therapy account, written for a category that has to be careful.
Describe Without Claiming
Content that says what a drip contains, not what a disease it cures.
Explain Who Is Treating
Nurse, prescriber and oversight, which is what separates you from a juice bar.
Build The Repeat Habit
A one-time purchase that only becomes a business if people return.
Replies That Name Nobody
A review answered without confirming anyone was ever a client here.
Other medical and dental practices we set up differently
IV therapy sits next to the other practices selling wellness services under clinical rules.
Marketing by company size
The same platform, framed by how many locations you run, not by what you treat.
You have questions. We have answers.
What comes up on the first call with an IV therapy business.
How far can we go on benefit claims?
Not as far as most of this industry does. The FTC's first action in this sector, in 2018, concerned claims that IV cocktails could treat conditions including cancer and multiple sclerosis. The safe ground is describing contents and experience instead of promising outcomes.
Is the compounding point relevant to us?
Directly. Compounded drugs are not FDA approved and FDA does not verify their safety, effectiveness or quality before marketing, and 503A compounding is tied to patient-specific prescriptions. That shapes what you can prepare in advance and it is worth understanding before it shapes a regulator's letter.
What content works if we cannot make claims?
Process and people. Who assesses you, what is in the bag, what the appointment is like, what it does not do. Restraint reads as competence in a category with a reputation for the opposite.
Our customers come once and never return.
Which makes this a very expensive business to run on acquisition alone. The businesses that work build a repeat habit around a reason, and almost nobody sends anything after the first visit.
Sources
- Federal Trade Commission, FTC Brings First-ever Action Targeting iV Cocktail Therapy Marketer, 20 September 2018, final consent order approved 21 February 2019, read 24 September 2026. A single respondent, binding only on that company.
- United States Food and Drug Administration, Compounding and the FDA: Questions and Answers, content current as of 16 September 2025, read 24 September 2026
Ready to Grow Your Business?
Find out how MoFlo's AI can take the work off your plate and power your business growth.